Spiroazabicyclic Heterocyclic Compounds

Abstract

A compound of formula wherein n, m, p, X, Y, W, A, G and D are as defined in the specification, enantiomers thereof, pharmaceutical compositions containing said compound, pharmaceutically acceptable salts thereof, its use in therapy, especially in the treatment of psychotic disorders and intellectual impairment disorders.

1 - 32 . (canceled) 
     
     
         33 . Spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine] or an enantiomer thereof. 
     
     
         34 . A compound according to  claim 33  in (R)-enantiomeric form. 
     
     
         35 . A compound according to  claim 34  crystallized as the D-(−)-tartrate. 
     
     
         36 . A pharmaceutical composition comprising a compound as defined in  claim 34 . 
     
     
         37 . A pharmaceutical composition according to  claim 36  comprising an inert pharmaceutically acceptable diluent or carrier. 
     
     
         38 . A pharmaceutical composition comprising a compound as defined in  claim 35 . 
     
     
         39 . A pharmaceutical composition according to  claim 38  comprising an inert pharmaceutically acceptable diluent or carrier. 
     
     
         40 . A method of treating human diseases or conditions in which activation of the α7 nicotinic receptor is beneficial which comprises administering a therapeutically effective amount of a compound as defined in  claim 34 . 
     
     
         41 . A method of treating psychotic disorders or intellectual impairment disorders, which comprises administering a therapeutically effective amount of a compound as defined in  claim 34 . 
     
     
         42 . A method according to  claim 41 , wherein the disorder is Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, or Attention Deficit Hyperactivity Disorder. 
     
     
         43 . A method according to  claim 41 , wherein the disorder is Parkinson's disease, Huntington's disease, Tourette's syndrome, or a neurodegenerative disorder in which there is loss of cholinergic synapses. 
     
     
         44 . A method according to  claim 41 , wherein the disorder is anxiety, schizophrenia, mania or manic depression.